Time to resolution of morbidity: An endpoint for assessing the clinical cure of community-acquired pneumonia

Respiratory Medicine

Volumn 90, Issue 10, 1996, Pages 587-592

  Daifuku, R ^a   Movahhed, H ^a   Fotheringham, N ^a   Bear, M B ^a   Nelson, S ^b  

^a AMGEN INC   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBIOTIC THERAPY; ARTICLE; BODY TEMPERATURE; BREATHING RATE; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORBIDITY; MULTICENTER STUDY; OBSERVER VARIATION; OXYGENATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; TIME;

EID: 0029903376     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90016-5     Document Type: Article

References (16)

1. Center for Disease Control. Mortality Patterns - United States, 1987. MMWR 1990; 39: 193-201.
2. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991; 115: 428-436.
3. Fine MJ, Orloff JJ, Arisumi D et al. Prognosis of patients hospitalized with community-acquired. pneumonia. Am J Med 1990; 88 (5N): 1N-8N.
4. Örtqvist Å, Hedlund J, Grillner L et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990; 3: 1105-1113.
5. Rello J, Quintana E, Ausina V et al. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest 1993; 103: 232-235.
6. McKellar PP. Treatment of community acquired pneumonia. Am J Med 1985; 79 (2A): 25-31.
7. Chow AW, Hall CB, Klein JO et al. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992; 15 (Suppl. 1): S62-88.
8. Hebert JC, O'Reilly M, Gamelli RL. Protective effect of recombinant human granulocyte colony stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 1990; 125: 1075-1078.
9. Nelson S, Summer W, Bagby G et al. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 1991; 164: 901-906.
10. deBoisblanc BP, Summer WR, Mason C et al. Phase I trial of granulocyte colony stimulating factor in severe community acquired pneumonia. Am Rev Resp Dis 1993; 147: A204.
11. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. JAMA 1987; 258: 1143-1153.
12. Fine MJ. Pneumonia in the elderly: the hospital admission and discharge decisions. Semin Respir Infect 1990; 5: 303-313.
13. Gleckman RA, Bergman MM. Bacterial pneumonia: specific diagnosis and treatment of the elderly. Geriatrics 1987; 42: 29-41.
14. Wijnands GJ. Diagnosis and interventions in lower respiratory tract infections. Am J Med 1992; 92 (Suppl. 4A): 91S-97S.
15. Albert RK. Evaluation of the patient with cyanosis or hypoxemia. In: Kelly WN, ed. Textbook of Internal Medicine. Philadelphia: JB Lippincott, 1992; 1874-1877.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.